Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer
Authors:
- Zhangjian HuangZHZhangjian Huang
- Ledong WanLWLedong Wan
- Sixun PengSPSixun Peng
- Ke DingKDKe Ding
- Hongbin JiHJHongbin Ji
- Yihua ZhangYZYihua Zhang
- 24 May 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 56 (11) , 4738-4748
Abstract
A series of hybrids (12a–k) from (phenylsulfonyl)furoxan and anilinopyrimidine were synthesized and biologically evaluated as epidermal growth factor receptor (EGFR) inhibitors for intervention of non-small-cell lung cancer (NSCLC). Compound 12k exhibited strong and selective EGFR L858R/T790M inhibitory activity (IC50 = 0.047 μM) and displayed antiproliferative effects on EGFR mutation NSCLC cell lines HCC827 (del E746_A750) and H1975 (L858R/T790M) with IC50 values of 0.007 and 0.029 μM, respectively. Additionally, 12k released high levels of NO in H1975 cells but not in normal human cells, and its activity was diminished by pretreatment with a NO scavenger. Furthermore, 12k induced apoptosis of H1975 and HCC827 cells more strongly than WZ4002 (1), inhibited EGFR downstream signaling in H1975 cells, and suppressed the nuclear factor-κB activation in H1975 cells, while 1 had no significant effects under the same conditions. Finally, 12k substantially inhibited tumor growth in an H1975 xenograft mouse model. Overall, 12k might be a promising candidate for the treatment of NSCLC.Keywords
This publication has 36 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Nitric oxide release: Part III. Measurement and reportingChemical Society Reviews, 2012
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFRNature, 2011
- Discovery of selective irreversible inhibitors for EGFR-T790MBioorganic & Medicinal Chemistry Letters, 2011
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790MNature, 2009
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences, 2008
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLOS Medicine, 2005
- Nitric oxide suppresses inducible nitric oxide synthase expression by inhibiting post-translational modification of IκBExperimental & Molecular Medicine, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000